Genmab — November 2016
-
Jeg sagde jo, at I skulle nyde slutspurten.

-
Men det kunne vil tænkes, at den generellet appetit på Genmap og Biotek, fortsætter og driver kursen op? IBB og NBI fortsætter op

-
IBB 8,16 %
-
Er det mon på tisotumab nyhederne i morgen?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind